Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The clinical impact of anti-DNA antibodies lies on their diagnostic power for systemic lupus erythematosus (SLE), being a formal classification criterion. In spite of such a disease association, low-avidity anti-DNA antibodies might also be part of the natural autoantibody repertoire. Their switch to pathogenic high-avidity autoantibodies is the result of the autoimmune process leading to SLE.Anti-DNA antibodies were shown to play a role in SLE pathogenesis and particularly in kidney damage. Accordingly, antibody titres might fluctuate in relation to disease activity, but their prognostic value for flares is still debated.Several methods for anti-DNA detection were described and there is evidence that the assays identify different antibodies with different prognostic value. The results of a multicenter study on four different routine tests for anti-dsDNA antibody detection showed that: (i) Farr assay displays the best diagnostic specificity/sensitivity for SLE, followed by Crithidia luciliae method (CLIFT), (ii) the new generation of solid phase assay (EliA) shows an increased sensibility versus the classical enzyme linked immune assay (ELISA) but a decreased specificity. Antibody titre detected by EliA and Farr assay correlated with disease activity. These findings would suggest that more than one assay should be useful for SLE diagnosis and monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of relapses in systemic lupus erythematosus
Bootsma, H., Spronk, P., de Boer, G., Limburg, P., Kallenberg, C., Derksen, R., Wolters-Dicke, J., Gmelig-Meyling, F., Kater, L., & Hermans, J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90114-0 · Cited by 290 · cited 1×
“Accordingly, a corticosteroid treatment started as soon as the antibody titre increase was found to result in the prevention of relapses in most cases without increasing the cumulative corticosteroid dosage [17].”
BackgroundSwaak, T., & Smeenk, R. (1985) · Annals of the Rheumatic Diseases · doi:10.1136/ard.44.4.245 · Cited by 89 · cited 1×
“Up to 85% of the Farr positive subjects developed SLE after 5 years of follow-up versus 52% only in the group with a positivity for PEG but with a negativity for the Farr assay [ 16 ].”
Background
Cited by
Gordon, C., Amissah-Arthur, M.-B., Gayed, M., Brown, S., Bruce, I. N., D’Cruz, D., Empson, B., Griffiths, B., Jayne, D., Khamashta, M., et al. (2018) · Rheumatology · doi:10.1093/rheumatology/kex286 · Cited by 365
Wichainun, R. (2013) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap0272.31.4.2013 · Cited by 82
European attempts to set guidelines for improving diagnostics of autoimmune rheumatic disorders
Wiik, A., Cervera, R., Haass, M., Khamashta, M., Meroni, P., Piette, J.-C., Schmitt, R., & Shoenfeld, Y. (2006) · Lupus · doi:10.1191/0961203306lu2322oa · Cited by 44
Self-citationJaekel, H.-P., Trabandt, A., Grobe, N., & Werle, E. (2006) · Lupus · doi:10.1191/0961203306lu2308oa · Cited by 43
(2011) · PubMed · Cited by 41
Metadata
- Authors
- Riboldi, P., Gerosa, M., Moroni, G., Radice, A., Allegri, F., Sinico, A., Tincani, A., & Meroni, P. L.
- Venue
- Autoimmunity
- Publisher
- Informa UK Limited
- Published
- 2005-02
- Volume
- 38
- Issue
- 1
- Pages
- 39-45
- ISSN
- 0891-6934 (ISSN-L)
- 1607-842X
- OpenAlex
- W2091100083
- Cited by
- 106
- References
- 2
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? https://app.cochat.ai/papers/10.1080/08916930400022616
- The paper
- Riboldi, P., Gerosa, M., Moroni, G., Radice, A., Allegri, F., Sinico, A., Tincani, A., & Meroni, P. L. (2005). Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity. https://doi.org/10.1080/08916930400022616
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.